Step 4: preparation of intermediate tert-butyl 7-(allyloxyamino)-3-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-2-oxo-6,7-dihydro-4H-thiazolo[4,5-c]pyridine-5-carboxylate (10d)
Using the procedure described in example 3 (step 10), tert-butyl 7-[allyloxy-(2-nitrophenyl)sulfonyl-amino]-3-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-2-oxo-6,7-dihydro-4H-thiazolo[4,5-c]pyridine-5-carboxylate (10c) (587 mg, 0.86 mmol) was converted to tert-butyl 7-(allyloxyamino)-3-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-2-oxo-6,7-dihydro-4H-thiazolo[4,5-c]pyridine-5-carboxylate (10d) (334 mg, 0.669 mmol, 78%) after a purification on silica gel (DCM/EtOAc 100/0 to 80/20).